LeanBio Therapeutics, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
Pre-open
Investors
—
Min Invest
None stated
What this filing shows
·Every sentence is a value as filed on SEC Form D
LeanBio Therapeutics, Inc. is a Delaware corporation organized in 2026 that filed a Form D with the SEC on October 22, 2026 in the Biotechnology industry group. The offering claims Rule 506(b), Section 4(a)(5) and covers equity. LeanBio Therapeutics, Inc. reported that the first sale had not yet occurred as of the Form D filed October 22, 2026, so no amount sold or investor count is on file. The total offering amount is listed as indefinite. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 80 Park Street, Apt Ph, Brookline, MA 02446.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Oct 22, 2026
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
pre_sale
Latest event New filer · Oct 22, 2026
SEC.govInvestor
- 1 filing event with values and deltas, latest 2026-10-22, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Michal Preminger
Executive Officer, Director · Brookline, MA
William Hait
Executive Officer, Director · Brookline, MA
Questions About LeanBio Therapeutics, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is LeanBio Therapeutics, Inc.?
LeanBio Therapeutics, Inc. is a Delaware corporation organized in 2026 that filed a Form D with the SEC on October 22, 2026 in the Biotechnology industry group. The filing claims Rule 506(b), Section 4(a)(5) for an offering of equity.
Is LeanBio Therapeutics, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. LeanBio Therapeutics, Inc. filed a Form D with the SEC on October 22, 2026 claiming Rule 506(b), Section 4(a)(5). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is LeanBio Therapeutics, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that LeanBio Therapeutics, Inc. claimed Rule 506(b), Section 4(a)(5) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has LeanBio Therapeutics, Inc. raised?
LeanBio Therapeutics, Inc. reported that the first sale had not yet occurred as of the Form D filed October 22, 2026, so no amount sold or investor count is on file. The total offering amount is listed as indefinite.
Who can invest in LeanBio Therapeutics, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in LeanBio Therapeutics, Inc.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling LeanBio Therapeutics, Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind LeanBio Therapeutics, Inc.?
The Form D lists 2 related persons: Michal Preminger, executive officer, director; William Hait, executive officer, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is LeanBio Therapeutics, Inc. located?
The issuer's address on its SEC filings is 80 Park Street, Apt Ph, Brookline, MA 02446. Its phone number of record is 716-6557788. It is organized under the laws of Delaware.
How long is the LeanBio Therapeutics, Inc. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is LeanBio Therapeutics, Inc.'s revenue?
The Form D reports a revenue range of No Revenues.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.